dd380cc5-9181-46c9-a80e-9c3f2b8cbd70
ITS MiSeq sequencing data: IFX response in PIBD
Pediatric inflammatory bowel disease (PIBD) is a globally increasing chronic inflammatory disease associated with an imbalanced intestinal microbiota and treated successfully with multiple treatments options, including  anti-tumor necrosis factor alpha (TNF-a), such as infliximab (IFX). Up to half of the patients do not respond to the drug and there are no methods for response prediction. Our aim was to identify predictive biomarkers from the gut microbiota composition since these are largely unexplored in patients with PIBD. The gut microbiota of 30 PIBD patients receiving IFX was studied by MiSeq sequencing targeting 16S and ITS region from fecal samples collected before treatment initiation and two and six weeks after start of treatment. The response to IFX induction was determined by a fecal calprotectin value below 100 µg/g at week six after first infusion. The bacterial microbiota differed significantly between response groups, with higher relative abundance of butyrate-producing bacteria in responders compared to non-responders at baseline, validated by high predictive power (area under curve = 0.892) for baseline Ruminococcus and calprotectin. Additionally, non-responders had higher abundance of Candida, while responders had higher abundance of Saccharomyces at the end of the study. The gut microbiota composition in PIBD patients could predict response to IFX treatment in the future.
Pediatric inflammatory bowel disease (PIBD) is a globally increasing chronic inflammatory disease associated with an imbalanced intestinal microbiota and treated successfully with multiple treatments options, including  anti-tumor necrosis factor alpha (TNF-a), such as infliximab (IFX). Up to half of the patients do not respond to the drug and there are no methods for response prediction. Our aim was to identify predictive biomarkers from the gut microbiota composition since these are largely unexplored in patients with PIBD. The gut microbiota of 30 PIBD patients receiving IFX was studied by MiSeq sequencing targeting 16S and ITS region from fecal samples collected before treatment initiation and two and six weeks after start of treatment. The response to IFX induction was determined by a fecal calprotectin value below 100 µg/g at week six after first infusion. The bacterial microbiota differed significantly between response groups, with higher relative abundance of butyrate-producing bacteria in responders compared to non-responders at baseline, validated by high predictive power (area under curve = 0.892) for baseline Ruminococcus and calprotectin. Additionally, non-responders had higher abundance of Candida, while responders had higher abundance of Saccharomyces at the end of the study. The gut microbiota composition in PIBD patients could predict response to IFX treatment in the future.